Abstract:
This study examined all cases of Staphylococcus aureus bacteraemia (SAB) in the haemodialysis cohort at the Royal Darwin Hospital, Australia over a seven-year period. Midway through this period, antisepsis for arteriovenous fistulae (AVF) and central venous catheters (CVC) changed from 0.5% chlorhexidine solution to 2% chlorhexidine solution.
[ctt tweet=”ReTweet if useful… Most effective skin antisepsis prior to vascular access procedures http://ctt.ec/C1dIE+ @ivteam #ivteam” coverup=”C1dIE”]
Rates of SAB episodes were calculated using registry data. Trends in SAB over time were analysed using an interrupted regression analysis. Following the change to 2% chlorhexidine, average SAB rates decreased by 68%, and it is estimated that 0.111 cases of SAB/patient-year were prevented. CVC-related SAB rates remained low throughout. These results support the use of 2% chlorhexidine in skin antisepsis for patients with AVF.
Reference:
Stewart, B.J., Gardiner, T., Perry, G.J. and Tong, S.Y. (2015) Reduction in Staphylococcus aureus bacteraemia rates in patients receiving haemodialysis following alteration of skin antisepsis procedures. The Journal of Hospital Infection. December 1st. [epub ahead of print].
DOI: 10.1016/j.jhin.2015.10.022.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]